weight loss, Safe and Ozempic

Novo Nordisk CEO: side-effects not a problem in CagriSema study
Novo Nordisk's CEO said on Wednesday side-effects were not a problem in the trial of its next-generation obesity drug ...
FiercePharma2d
'We cannot stay silent': Novo Nordisk flags dangers of compounded GLP-1s following Hims & Hers Super Bowl ad
The “Check Before You Inject” ad goes on to note that some vials of compounded semaglutide “have been found to contain ...
Investors are growing anxious about Novo Nordisk’s silence since disappointing CagriSema weight loss drug results
Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.
Novo Nordisk Faces Investor Concerns Over Hybrid CagriSema Trial Results For Weight Loss
Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors ...
Novo Nordisk's next-gen obesity drug Cagrisema: investors seek answers
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
MedCity News10d
Oral Metabolic Drug Acquired by Novo Nordisk Continues to Show Concerning Neuro Side Effects
Last September, Novo Nordisk reported Phase 2 obesity study results showing statistically significant weight loss at 16 weeks across all three doses tested. While gastrointestinal side ...
Super Bowl ad for Hims & Hers' weight loss drug sparks backlash
The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, ...
FierceBiotech10d
Novo flunks kidney disease trial, again linking obesity prospect to neuropsychiatric side effects
Novo Nordisk’s cannabinoid CB1 receptor blocker has run into another problem. | Novo Nordisk’s cannabinoid CB1 receptor blocker has run into another problem. Months after sharing obesity data that ...